Valeant Stock Slides After Profit Forecast Is Chopped

Valeant returned to slashing its annual outlook, signaling the pharmaceutical company is still hemorrhaging from missteps over the past year and indicating it may take longer than expected to remake its business.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news
More News: Pharmaceuticals